{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01966471",
      "orgStudyIdInfo": {
        "id": null,
        "type": null,
        "link": null
      },
      "secondaryIdInfos": [],
      "organization": {
        "fullName": "F. Hoffmann-La Roche/Genentech",
        "class": "INDUSTRY"
      },
      "briefTitle": "KAITLIN: Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk HER2-Positive Early Breast Cancer",
      "officialTitle": "Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study",
      "acronym": "KAITLIN"
    },
    "descriptionModule": {
      "briefSummary": "This phase III randomized, multinational KAITLIN study evaluated whether replacing standard taxane plus trastuzumab (with pertuzumab) with trastuzumab emtansine (T-DM1) plus pertuzumab, after anthracycline-based chemotherapy and surgery, could improve outcomes and reduce toxicity in adults with high-risk HER2-positive early breast cancer. High risk was defined as node-positive disease or node-negative, hormone receptor–negative tumors larger than 2 cm. Patients were randomly assigned to receive anthracycline-based chemotherapy followed by either taxane plus trastuzumab plus pertuzumab (AC-THP) or T-DM1 plus pertuzumab (AC-KP) for about one year. The main outcome was invasive disease-free survival, assessed first in node-positive patients and then in the overall population. The study found no significant improvement in invasive disease-free survival with T-DM1 plus pertuzumab compared with taxane plus trastuzumab plus pertuzumab, although both regimens achieved high 3-year invasive disease-free survival rates. Overall safety profiles were consistent with prior experience, and quality-of-life deterioration during HER2-targeted therapy was less frequent with T-DM1 plus pertuzumab, largely due to avoidance of taxane-related toxicity.",
      "detailedDescription": "KAITLIN (NCT01966471) is a phase III, randomized, open-label, multinational clinical trial conducted in 288 centers across 36 countries to investigate adjuvant treatment strategies for high-risk HER2-positive early breast cancer (EBC). Eligible patients were adults with newly diagnosed, operable, nonmetastatic, histologically confirmed HER2-positive invasive breast carcinoma that had been surgically excised. High risk was defined as either (1) lymph node–positive disease (pN ≥ 1), with any tumor size except T0 and any hormone receptor status, or (2) node-negative disease (pN0) with tumor size > 2.0 cm and hormone receptor–negative status (estrogen receptor– and progesterone receptor–negative). HER2 positivity was centrally confirmed by immunohistochemistry (IHC 3+) and/or in situ hybridization (HER2:chromosome 17 ratio ≥ 2.0).\n\nWithin 9 weeks after definitive breast surgery, patients were randomized 1:1 to one of two adjuvant treatment arms, both beginning with anthracycline-based chemotherapy (three or four cycles of investigator’s choice of FEC, AC, or EC). After completion of anthracycline therapy and an interval of at least 3 weeks, patients received HER2-targeted therapy for a planned duration of one year, in combination with either a taxane or trastuzumab emtansine (T-DM1):\n\n• Control arm (AC-THP): anthracycline chemotherapy followed by a taxane (docetaxel or paclitaxel) plus trastuzumab and pertuzumab. Trastuzumab was given every 3 weeks (8 mg/kg loading, then 6 mg/kg), and pertuzumab every 3 weeks (840 mg loading, then 420 mg). After completion of the taxane phase, trastuzumab plus pertuzumab was continued to complete at least one year of HER2-targeted therapy.\n\n• Experimental arm (AC-KP): anthracycline chemotherapy followed by T-DM1 plus pertuzumab. T-DM1 was administered at 3.6 mg/kg every 3 weeks, with pertuzumab dosed as in the control arm, for a total planned duration of at least one year of HER2-targeted therapy.\n\nDose delays and reductions were permitted for anthracyclines, taxanes, and T-DM1; only delays (no reductions) were allowed for trastuzumab and pertuzumab. For patients in the T-DM1 arm who discontinued T-DM1 due to toxicity, a switch to trastuzumab was recommended to complete at least one year of HER2-directed therapy. Adjuvant radiotherapy and/or endocrine therapy was administered as clinically indicated, typically after taxane chemotherapy in the control arm or after four cycles of T-DM1 in the experimental arm.\n\nThe coprimary efficacy endpoints were invasive disease-free survival (IDFS) in the intention-to-treat node-positive population and in the overall randomized population. IDFS was defined as time from randomization to first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral or ipsilateral second primary invasive breast cancer, distant recurrence, or death from any cause. Secondary endpoints included IDFS plus second primary nonbreast cancer, disease-free survival (including ductal carcinoma in situ events), distant recurrence-free interval, and overall survival (OS). Adverse events were assessed using CTCAE v4.0. Cardiac endpoints included adjudicated primary cardiac events (severe heart failure, significant LVEF decline, or cardiac death) and secondary cardiac events (symptomatic or asymptomatic LV systolic dysfunction with LVEF decline). Patient-reported outcomes (PROs) were measured by the EORTC QLQ-C30 and QLQ-BR23 questionnaires, focusing on global health status/quality of life, functioning, and symptoms, with clinically meaningful deterioration generally defined as a ≥ 10-point decrease from baseline.\n\nThe statistical design targeted approximately 171 IDFS events in the overall population and 160 in the node-positive subpopulation to provide ~80–82.5% power to detect a hazard ratio (HR) of 0.64 at a two-sided 5% significance level using a stratified log-rank test. A hierarchical testing procedure controlled the overall type I error at 5%: IDFS in node-positive patients, then IDFS in the overall population, followed by OS in node-positive patients and OS in the overall population. After results from the metastatic MARIANNE trial indicated noninferiority but not superiority of T-DM1-based regimens versus taxane plus trastuzumab, the planned sample size in KAITLIN was reduced from 2,500 to approximately 1,850 patients without altering the event-driven power assumptions.\n\nBetween January 2014 and June 2015, 1,846 patients were enrolled (918 AC-THP; 928 AC-KP); 1,658 (89.8%) were node-positive. Median follow-up was about 57 months in both arms. There were 82 (9.9%) IDFS events in the AC-THP arm and 80 (9.6%) in the AC-KP arm among node-positive patients, yielding a stratified HR of 0.97 (95% CI, 0.71–1.32; P = .83). Because the primary comparison in node-positive patients was not statistically significant, hierarchical testing was stopped. In the overall population, 88 (9.6%) and 86 (9.3%) IDFS events occurred in the AC-THP and AC-KP arms, respectively (stratified HR, 0.98; 95% CI, 0.72–1.32). Three-year IDFS rates in the overall population were 94.2% (95% CI, 92.7–95.8) for AC-THP and 93.1% (95% CI, 91.4–94.7) for AC-KP, with similar patterns in node-positive patients. Secondary endpoints, including disease-free survival and distant recurrence-free interval, were also comparable between arms. OS data were immature at the time of analysis, with low event rates (3.6% vs 4.7% in AC-THP vs AC-KP).\n\nIn the safety population (1,838 treated patients), completion of all 18 cycles of trastuzumab or T-DM1 occurred in 88.4% of AC-THP patients and 65.0% of AC-KP patients; when including those who switched from T-DM1 to trastuzumab, 81.5% in AC-KP completed planned HER2-directed therapy. Grade 3 or higher adverse events and serious adverse events occurred at similar rates across arms (approximately 55% vs 52% for grade ≥ 3 events and 23% vs 21% for serious adverse events in AC-THP vs AC-KP). Discontinuation of T-DM1 was notably higher than for trastuzumab (26.8% vs 4.0%), mainly because of laboratory abnormalities such as elevated bilirubin and thrombocytopenia. Overall cardiac event rates were low in both arms, with slightly fewer primary and secondary cardiac events in the T-DM1 arm. T-DM1 was associated with increased rates of hepatotoxicity, thrombocytopenia, and hemorrhage compared to the taxane–trastuzumab regimen, while taxane-related toxicities (e.g., neuropathy, myalgia, arthralgia, and alopecia) are acknowledged but detailed incidence values are not fully reported in the extract.\n\nPRO analyses showed that during the anthracycline phase, patients in both arms experienced deterioration in quality of life and functioning. From the start of HER2-targeted therapy, functioning stabilized in the AC-KP arm but continued to worsen in the AC-THP arm during taxane administration, then improved after taxane completion, ultimately converging with AC-KP. Time-to-event analyses demonstrated a 29% reduction in risk of clinically meaningful deterioration in global health status/quality of life from the start of HER2-targeted therapy in the AC-KP arm compared with AC-THP (stratified HR, 0.71; 95% CI, 0.62–0.80), with similar patterns for physical and role functioning.\n\nOverall, KAITLIN did not demonstrate superiority of adjuvant anthracycline followed by T-DM1 plus pertuzumab over anthracycline followed by taxane plus trastuzumab plus pertuzumab in terms of IDFS in high-risk HER2-positive early breast cancer. Both regimens achieved high IDFS rates and had safety profiles consistent with previous experience. The trial supports the continued use of taxane plus trastuzumab plus pertuzumab–based chemotherapy as the standard adjuvant regimen in this setting. In the context of evolving treatment paradigms, where neoadjuvant trastuzumab/pertuzumab plus chemotherapy followed by adjuvant T-DM1 for residual disease is now standard, these results reinforce a tailored strategy that maintains intensive HER2-targeted therapy while exploring chemotherapy de-escalation in selected patients and therapy escalation (including T-DM1) for those with residual high-risk disease."
    },
    "conditionsModule": {
      "conditions": [
        "Breast Neoplasms",
        "Breast Neoplasms, HER2-Positive",
        "Early Breast Cancer",
        "Carcinoma, Ductal, Breast"
      ],
      "keywords": [
        "HER2-positive breast cancer",
        "Early breast cancer",
        "High-risk breast cancer",
        "Adjuvant chemotherapy",
        "Anthracyclines",
        "Taxanes",
        "Trastuzumab",
        "Pertuzumab",
        "Trastuzumab emtansine",
        "T-DM1",
        "Antibody-drug conjugates",
        "Invasive disease-free survival",
        "Disease-free survival",
        "Distant recurrence-free interval",
        "Overall survival",
        "Quality of life",
        "EORTC QLQ-C30",
        "EORTC QLQ-BR23",
        "Cardiotoxicity",
        "Hepatotoxicity",
        "Thrombocytopenia",
        "Adjuvant therapy",
        "Node-positive breast cancer",
        "Hormone receptor–negative breast cancer"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "patientRegistry": false,
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Multinational, randomized, open-label, parallel-group phase III trial comparing anthracycline-based chemotherapy followed by taxane plus trastuzumab plus pertuzumab (AC-THP) versus anthracycline-based chemotherapy followed by trastuzumab emtansine plus pertuzumab (AC-KP) in high-risk HER2-positive early breast cancer.",
        "primaryPurpose": "TREATMENT",
        "observationalModel": "COHORT",
        "timePerspective": "PROSPECTIVE",
        "maskingInfo": {
          "masking": "NONE",
          "maskingDescription": "Open-label study with no blinding; treatment assignments were known to investigators and participants.",
          "whoMasked": []
        }
      },
      "enrollmentInfo": {
        "count": 1846,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "AC-THP",
          "type": "ACTIVE_COMPARATOR",
          "description": "Anthracycline-based chemotherapy (three or four cycles of investigator's choice regimen: FEC, AC, or EC) followed by a taxane (docetaxel or paclitaxel, three or four cycles) plus trastuzumab and pertuzumab. Trastuzumab and pertuzumab were started concurrently with the taxane after an interval of at least 3 weeks from the last anthracycline dose, and trastuzumab plus pertuzumab was continued to complete at least 1 year (18 cycles) of HER2-targeted therapy. Dose delays/reductions were allowed for anthracyclines and taxanes; only dose delays for trastuzumab and pertuzumab.",
          "interventionNames": [
            "Doxorubicin",
            "Epirubicin",
            "Cyclophosphamide",
            "Fluorouracil",
            "Docetaxel",
            "Paclitaxel",
            "Trastuzumab",
            "Pertuzumab"
          ]
        },
        {
          "label": "AC-KP",
          "type": "EXPERIMENTAL",
          "description": "Anthracycline-based chemotherapy (three or four cycles of investigator's choice regimen: FEC, AC, or EC) followed by trastuzumab emtansine (T-DM1) plus pertuzumab. T-DM1 was dosed at 3.6 mg/kg once every 3 weeks and pertuzumab at 840-mg loading dose then 420 mg every 3 weeks, both started after an interval of at least 3 weeks from the last anthracycline dose and continued for at least 1 year (18 cycles) of HER2-targeted therapy. Dose delays/reductions were allowed for anthracyclines and T-DM1; only dose delays for pertuzumab. Patients discontinuing T-DM1 for toxicity were recommended to switch to trastuzumab to complete at least 1 year of HER2-directed therapy.",
          "interventionNames": [
            "Doxorubicin",
            "Epirubicin",
            "Cyclophosphamide",
            "Fluorouracil",
            "Trastuzumab emtansine",
            "Pertuzumab",
            "Trastuzumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Doxorubicin",
          "description": "Anthracycline cytotoxic agent (component of AC regimen) administered in three or four cycles as part of initial anthracycline-based chemotherapy before HER2-targeted therapy.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Epirubicin",
          "description": "Anthracycline cytotoxic agent (component of EC or FEC regimen) administered in three or four cycles as part of initial anthracycline-based chemotherapy before HER2-targeted therapy.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Cyclophosphamide",
          "description": "Alkylating agent combined with doxorubicin or epirubicin in AC or EC (and FEC) regimens given as three or four cycles of anthracycline-based chemotherapy pre-HER2-targeted treatment.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Fluorouracil",
          "description": "Antimetabolite chemotherapeutic used in the FEC regimen (fluorouracil, epirubicin, cyclophosphamide) as part of three or four cycles of anthracycline-based chemotherapy before HER2-targeted therapy.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Docetaxel",
          "description": "Taxane chemotherapeutic agent administered for three or four cycles, concurrently with trastuzumab and pertuzumab, after completion of anthracycline-based chemotherapy in the AC-THP arm.",
          "armGroupLabels": [
            "AC-THP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Paclitaxel",
          "description": "Taxane chemotherapeutic agent (alternative to docetaxel per investigator choice) administered for three or four cycles, concurrently with trastuzumab and pertuzumab, after anthracycline chemotherapy in the AC-THP arm.",
          "armGroupLabels": [
            "AC-THP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Trastuzumab",
          "description": "HER2-targeted monoclonal antibody dosed at an 8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks, started concurrently with the taxane in the AC-THP arm and continued with pertuzumab to complete at least 1 year of HER2-directed therapy. In the AC-KP arm, trastuzumab could be initiated if T-DM1 was discontinued, to complete at least 1 year of HER2-targeted therapy.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Pertuzumab",
          "description": "HER2-directed monoclonal antibody dosed at an 840-mg loading dose then 420 mg once every 3 weeks, administered concurrently with trastuzumab plus taxane in the AC-THP arm or with T-DM1 in the AC-KP arm, and continued for at least 1 year (18 cycles) of HER2-targeted therapy.",
          "armGroupLabels": [
            "AC-THP",
            "AC-KP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Trastuzumab emtansine",
          "description": "Antibody–drug conjugate (T-DM1) consisting of trastuzumab linked to the cytotoxic agent DM1, dosed at 3.6 mg/kg every 3 weeks and given concurrently with pertuzumab after anthracycline chemotherapy in the AC-KP arm for at least 1 year (18 cycles), with permitted dose reductions and delays for toxicity.",
          "armGroupLabels": [
            "AC-KP"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Invasive Disease-Free Survival (IDFS) in the node-positive subpopulation",
          "description": "Time from random assignment until the first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral or ipsilateral second primary invasive breast cancer, distant recurrence, or death from any cause in patients with node-positive disease.",
          "timeFrame": "From randomization until occurrence of an IDFS event or last known alive and event-free at data cutoff."
        },
        {
          "measure": "Invasive Disease-Free Survival (IDFS) in the overall population",
          "description": "Time from random assignment until the first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral or ipsilateral second primary invasive breast cancer, distant recurrence, or death from any cause in the overall intention-to-treat population.",
          "timeFrame": "From randomization until occurrence of an IDFS event or last known alive and event-free at data cutoff."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "IDFS plus second primary nonbreast cancer in the node-positive subpopulation",
          "description": "Composite of IDFS events plus occurrence of a second primary nonbreast cancer, assessed in patients with node-positive disease.",
          "timeFrame": "From randomization until first IDFS event or second primary nonbreast cancer, or last known alive and event-free at data cutoff."
        },
        {
          "measure": "IDFS plus second primary nonbreast cancer in the overall population",
          "description": "Composite of IDFS events plus occurrence of a second primary nonbreast cancer, assessed in the overall intention-to-treat population.",
          "timeFrame": "From randomization until first IDFS event or second primary nonbreast cancer, or last known alive and event-free at data cutoff."
        },
        {
          "measure": "Disease-Free Survival (DFS) in the node-positive subpopulation",
          "description": "Time between random assignment and first occurrence of an IDFS event, second primary nonbreast cancer event, or contralateral or ipsilateral ductal carcinoma in situ in patients with node-positive disease.",
          "timeFrame": "From randomization until first DFS event or last known alive and event-free at data cutoff."
        },
        {
          "measure": "Disease-Free Survival (DFS) in the overall population",
          "description": "Time between random assignment and first occurrence of an IDFS event, second primary nonbreast cancer event, or contralateral or ipsilateral ductal carcinoma in situ in the overall intention-to-treat population.",
          "timeFrame": "From randomization until first DFS event or last known alive and event-free at data cutoff."
        },
        {
          "measure": "Distant Recurrence-Free Interval in the node-positive subpopulation",
          "description": "Time between random assignment and first occurrence of distant breast cancer recurrence in patients with node-positive disease.",
          "timeFrame": "From randomization until distant breast cancer recurrence or last known alive and distant-recurrence-free at data cutoff."
        },
        {
          "measure": "Distant Recurrence-Free Interval in the overall population",
          "description": "Time between random assignment and first occurrence of distant breast cancer recurrence in the overall intention-to-treat population.",
          "timeFrame": "From randomization until distant breast cancer recurrence or last known alive and distant-recurrence-free at data cutoff."
        },
        {
          "measure": "Overall Survival (OS) in the node-positive subpopulation",
          "description": "Time from random assignment to death from any cause in patients with node-positive disease.",
          "timeFrame": "From randomization until death from any cause or last known alive at data cutoff."
        },
        {
          "measure": "Overall Survival (OS) in the overall population",
          "description": "Time from random assignment to death from any cause in the overall intention-to-treat population.",
          "timeFrame": "From randomization until death from any cause or last known alive at data cutoff."
        },
        {
          "measure": "Adverse Events (AEs)",
          "description": "Incidence, type, and severity of adverse events coded by MedDRA and graded by NCI CTCAE v4.0, including grade 3 or higher AEs, serious AEs, and AEs leading to treatment discontinuation.",
          "timeFrame": "From first dose of study treatment through end of treatment and safety follow-up, as per study protocol."
        },
        {
          "measure": "Primary adjudicated cardiac safety events",
          "description": "Incidence of severe heart failure (NYHA class III or IV) and significant left ventricular ejection fraction (LVEF) decline (decline of ≥10 percentage points to a value <50%) or cardiac death, adjudicated by an independent clinical events committee.",
          "timeFrame": "From baseline (before anthracycline therapy) through completion of HER2-targeted therapy and safety follow-up."
        },
        {
          "measure": "Secondary cardiac safety events",
          "description": "Incidence of symptomatic left ventricular systolic dysfunction (NYHA class II) with significant LVEF decline and asymptomatic LVSD.",
          "timeFrame": "From baseline (before anthracycline therapy) through completion of HER2-targeted therapy and safety follow-up."
        },
        {
          "measure": "Patient-Reported Global Health Status/Quality of Life (QLQ-C30 Global Health/QOL)",
          "description": "Time to clinically meaningful deterioration in global health status/quality of life, defined as a decrease of ≥10 points from baseline on the EORTC QLQ-C30 Global Health/QOL scale.",
          "timeFrame": "From cycle 1 day 1 of HER2-targeted therapy until first clinically meaningful deterioration or last PRO assessment at data cutoff."
        },
        {
          "measure": "Patient-Reported Physical Functioning (QLQ-C30)",
          "description": "Time to clinically meaningful deterioration in physical functioning as measured by the EORTC QLQ-C30 physical functioning scale, using established minimally important difference thresholds.",
          "timeFrame": "From cycle 1 day 1 of HER2-targeted therapy until first clinically meaningful deterioration or last PRO assessment at data cutoff."
        },
        {
          "measure": "Patient-Reported Role Functioning (QLQ-C30)",
          "description": "Time to clinically meaningful deterioration in role functioning as measured by the EORTC QLQ-C30 role functioning scale, using established minimally important difference thresholds.",
          "timeFrame": "From cycle 1 day 1 of HER2-targeted therapy until first clinically meaningful deterioration or last PRO assessment at data cutoff."
        },
        {
          "measure": "Other Patient-Reported Outcomes (QLQ-C30 and QLQ-BR23 symptom and function scales)",
          "description": "Changes and time to clinically meaningful deterioration in additional EORTC QLQ-C30 and QLQ-BR23 function and symptom scales, including systemic therapy side effects, fatigue, diarrhea, and arm symptoms, defined using minimally important differences.",
          "timeFrame": "From cycle 1 day 1 of anthracycline treatment (for change-from-baseline analyses) and from cycle 1 day 1 of HER2-targeted therapy (for time-to-deterioration analyses) through end of treatment and follow-up assessments."
        }
      ],
      "otherOutcomes": []
    },
    "eligibilityModule": {
      "eligibilityCriteria": "- Inclusion Criteria:\n  - Adults with newly diagnosed, HER2-positive, nonmetastatic, histologically confirmed, operable primary invasive breast carcinoma\n  - Excised HER2-positive early breast cancer (EBC)\n  - Node-positive disease (pN ≥ 1), with any tumor size except T0 and any hormone receptor status, OR node-negative disease (pN0) with pathologic tumor size > 2.0 cm by local assessment and negative for estrogen receptor (ER) and progesterone receptor (PgR)\n  - HER2-positive status centrally confirmed, defined as:\n    - Immunohistochemistry (IHC) score of 3+ and/or\n    - In situ hybridization HER2:chromosome 17 ratio ≥ 2.0\n  - Baseline left ventricular ejection fraction (LVEF) ≥ 55% by echocardiogram or multigated acquisition scan\n  - Adults (age ≥ 18 years)\n  - Definitive breast surgery performed, with randomization within 9 weeks of surgery\n  - Written informed consent provided\n\n- Exclusion Criteria:\n  - Metastatic breast cancer\n  - Non-operable primary invasive breast carcinoma\n  - Pathologic tumor size ≤ 2.0 cm with node-negative and hormone receptor–negative disease (does not meet high-risk criteria)\n  - T0 tumors in the node-positive cohort\n  - HER2-negative disease by central assessment\n  - Baseline LVEF < 55%\n  - Inability to comply with protocol-specified anthracycline-based chemotherapy followed by HER2-targeted therapy\n  - Any condition that would make the patient ineligible per the complete eligibility criteria listed in the study’s Data Supplement (not fully detailed in the provided text)",
      "healthyVolunteers": false,
      "sex": "FEMALE",
      "minimumAge": "18 Years",
      "maximumAge": "N/A",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ],
      "studyPopulation": "",
      "samplingMethod": ""
    }
  }
}